MARKET

PEPG

PEPG

PepGen Inc
NASDAQ
7.17
+0.66
+10.14%
After Hours: 7.15 -0.02 -0.28% 19:31 01/02 EST
OPEN
6.48
PREV CLOSE
6.51
HIGH
7.80
LOW
6.28
VOLUME
1.99M
TURNOVER
--
52 WEEK HIGH
7.80
52 WEEK LOW
0.8801
MARKET CAP
492.92M
P/E (TTM)
-2.5282
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PEPG last week (1222-1226)?
Weekly Report · 12/29/2025 10:31
PepGen Buy Rating: De-Risked Safety and Potential Category-Leading Efficacy for PGN-EDODM1 in DM1 Ahead of 1Q26 MAD Readout
TipRanks · 12/23/2025 18:15
Weekly Report: what happened at PEPG last week (1215-1219)?
Weekly Report · 12/22/2025 10:31
Weekly Report: what happened at PEPG last week (1208-1212)?
Weekly Report · 12/15/2025 10:39
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 12/11/2025 21:05
PepGen Inc. Files Initial Statement of Beneficial Ownership for Chief Business & Legal Officer Joseph Vittiglio
Reuters · 12/10/2025 22:05
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44%
NASDAQ · 12/10/2025 14:55
PepGen Grants Stock Options to New Chief Business and Legal Officer
Reuters · 12/09/2025 12:00
More
About PEPG
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Webull offers PepGen Inc stock information, including NASDAQ: PEPG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEPG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PEPG stock methods without spending real money on the virtual paper trading platform.